Answers In CME

•

Canal • 6 podcasts

Ciências da vida

Ciências da vida

Semanal
Ciências da vida

Ciências da vida

Semanal
Ciências da vida

Ciências da vida

Semanal
Ciências da vida

Ciências da vida

Semanal
Ciências da vida

Ciências da vida

Semanal
Ciências da vida

Ciências da vida

Semanal

29 DE MAI.

Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

29 de mai.

•

15min
4 DE ABR.

Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer

Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

4 de abr.

•

22min
HÁ 3 DIAS

James F. Howard Jr., MD - C5 Inhibitors for the Treatment of Generalized Myasthenia Gravis: From Clinical Data to Patient-Centered Strategies

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

há 3 dias

•

15min
HÁ 5 DIAS

Mark A. Socinski, MD - Global Perspectives on Biomarker Testing in NSCLC: Clinical Insights on Optimizing Implementation in Practice

Please visit answersincme.com/ZDE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses best practices for implementing biomarker testing in non-small cell lung cancer (NSCLC) management. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations for biomarker testing to the management of patients with NSCLC, Outline practical strategies within the multidisciplinary team to optimize biomarker testing for patients with NSCLC; and Discuss methods to link biomarker testing to treatment decision-making for patients with NSCLC.

há 5 dias

•

13min
HÁ 6 DIAS

Venkataraman Raman Muthusamy, MD, MAS - A Window of Opportunity: Identifying the Risk of Esophageal Adenocarcinoma With Prognostic Testing

Please visit answersincme.com/URZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in esophageal carcinoma (EAC) discusses novel tests to predict the risk of progression from Barrett’s esophagus (BE) to EAC. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel prognostic stratification tests to predict the risk of progression from BE to EAC, Review the clinical support for prognostic tests that provide actionable information for identifying patients with BE who are at risk of progression to EAC; and Outline strategies to integrate novel prognostic tests into the surveillance algorithm for patients with BE who may be at risk of progression to EAC.

há 6 dias

•

17min
06/12/2024

Megan Huchko, MD, MPH - Isn't HPV Vaccination Only for Pre-Teens? Answering the Why and How of Adult Vaccination

Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.

06/12/2024

•

17min
04/07/2024

Jonathan Silverberg, MD, PhD, MPH - Taking a Hands-On Approach to the Management of Moderate to Severe Hand and Foot Atopic Dermatitis: Enhancing Patient Outcomes With Novel Systemic Therapies

Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.

04/07/2024

•

14min
2 DE ABR.

Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration

Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

2 de abr.

•

17min
HÁ 5 DIAS

Mark A. Socinski, MD - Global Perspectives on Biomarker Testing in NSCLC: Clinical Insights on Optimizing Implementation in Practice

Please visit answersincme.com/ZDE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses best practices for implementing biomarker testing in non-small cell lung cancer (NSCLC) management. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations for biomarker testing to the management of patients with NSCLC, Outline practical strategies within the multidisciplinary team to optimize biomarker testing for patients with NSCLC; and Discuss methods to link biomarker testing to treatment decision-making for patients with NSCLC.

há 5 dias

•

13min
17 DE JUN.

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Optimizing Survivorship Across the Patient Journey, Including Lines of Therapy

Please visit answersincme.com/860/27391-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in breast cancer discuss patient-centered strategies to optimize quality of life by implementing a proactive approach to adverse event management for HR+, HER2- mBC. Upon completion of this activity, participants should be better able to: Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations; and Identify proactive, patient-focused strategies to elevate survivorship for patients receiving ADCs for HR+, HER2- mBC.

17 de jun.

•

20min

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, followup, and clinical management of various medical conditions. Earning your CME/CE credit has never been faster or easier.

Site